Björn Dahlöf

Q: What Schools Are Affiliated With Björn Dahlöf

Björn Dahlöf is affiliated with the following schools: University of Oslo, University of Gothenburg

Björn Dahlöf's AcademicInfluence.com Rankings

Björn Dahlöf

Philosophy

#5242

World Rank

#7992

Historical Rank

Logic

#2552

World Rank

#3562

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Björn Dahlöf's Degrees

PhD Medicine University of Gothenburg

Why Is Björn Dahlöf Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Björn Dahlöf's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial (1998) (5865)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (2002) (5504)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial (2003) (2437)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri (2005) (2151)
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial (1999) (2032)
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (2002) (1631)
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) (1991) (1596)
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (2008) (1574)
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study (1999) (1470)
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension (2010) (1451)
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. (1992) (986)
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study (2000) (950)
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial (2012) (918)
Prognostic significance of left ventricular mass change during treatment of hypertension. (2004) (836)
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. (2008) (711)
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. (2005) (666)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ (2003) (611)
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study (2005) (603)
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension (2007) (590)
Telmisartan to prevent recurrent stroke and cardiovascular events. (2008) (583)
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. (2004) (574)
Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke (2010) (532)
Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. (1992) (487)
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial (2004) (481)
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. (2002) (469)
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial (2010) (443)
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (2002) (416)
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). (2005) (400)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. (1997) (356)
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) (2005) (325)
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo (2008) (320)
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. (1999) (317)
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy (2009) (314)
RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study (2007) (312)
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. (1998) (302)
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. (2006) (278)
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study (2003) (274)
Cardiovascular disease risk factors: epidemiology and risk assessment. (2010) (271)
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial (2001) (271)
Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Commentary (1992) (268)
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. (2001) (267)
Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction? (2008) (249)
Correlates of Left Atrial Size in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (2002) (245)
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. (2005) (240)
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. (2000) (236)
Surrogate markers for cardiovascular disease: structural markers. (2004) (232)
Effects of Once-Daily Angiotensin-Converting Enzyme Inhibition and Calcium Channel Blockade-Based Antihypertensive Treatment Regimens on Left Ventricular Hypertrophy and Diastolic Filling in Hypertension: The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PR (2001) (231)
Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2 (2000) (222)
Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor &kgr;B (2010) (194)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (2002) (178)
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study (2002) (177)
Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study (2007) (176)
Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial (2007) (175)
Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs (2016) (175)
Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials (1996) (170)
H35: Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study (1997) (161)
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. (2001) (160)
Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial (2004) (159)
The anglo-scandinavian cardiac outcomes trial (ASCOT) (1998) (159)
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. (2006) (154)
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. (2000) (150)
QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study (2004) (148)
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. (2002) (147)
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. (2004) (141)
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy (2004) (139)
Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report (2002) (134)
Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. (2000) (133)
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase (2018) (130)
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. (2004) (128)
Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients: The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study (2000) (128)
Echocardiographic Left Ventricular Geometry in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study (2001) (126)
Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients (2004) (126)
Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment (2002) (124)
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). (2008) (124)
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk (2011) (122)
Exceptional early blood pressure control rates: The ACCOMPLISH trial (2007) (119)
Cardiovascular events during differing hypertension therapies in patients with diabetes. (2010) (116)
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. (2009) (115)
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. (2006) (113)
Non-peptide AT2-receptor agonists. (2011) (110)
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. (2001) (110)
Relation between drug treatment and cancer In hypertenslves in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial (2001) (106)
Electrocardiographic Strain Pattern and Prediction of New-Onset Congestive Heart Failure in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study (2005) (104)
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. (2005) (104)
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study (2005) (102)
Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. (1990) (101)
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes (2008) (101)
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. (1995) (101)
Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study (2005) (100)
Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial (2008) (97)
Female sex as an important determinant of lisinopril-induced cough (1992) (97)
Direct Angiotensin II Type 2 Receptor Stimulation in N&ohgr;-Nitro-L-Arginine-Methyl Ester–Induced Hypertension: The Effect on Pulse Wave Velocity and Aortic Remodeling (2012) (96)
Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. (2001) (96)
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. (2010) (94)
Direct Stimulation of Angiotensin II Type 2 Receptor Enhances Spatial Memory (2012) (94)
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. (1999) (94)
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study (2002) (94)
Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. (1992) (94)
STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension. (1993) (92)
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE Study (2006) (88)
Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. (2001) (87)
Four-Group Classification of Left Ventricular Hypertrophy Based on Ventricular Concentricity and Dilatation Identifies a Low-Risk Subset of Eccentric Hypertrophy in Hypertensive Patients (2014) (87)
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study (2003) (87)
Change in Systolic Left Ventricular Performance After 3 Years of Antihypertensive Treatment: The Losartan Intervention for Endpoint (LIFE) Study (2002) (86)
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk (2002) (85)
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study (2003) (84)
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. (2002) (84)
Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study (2006) (82)
Antihypertensive efficacy and side effects of three beta‐blockers and a diuretic in elderly hypertensives: a report from the STOP‐Hypertension study (1992) (82)
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. (2002) (81)
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression (2013) (81)
Left ventricular hypertrophy and angiotensin II antagonists. (2001) (79)
Female preponderance for lisinopril-induced cough in hypertension. (1994) (76)
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). (2002) (75)
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study (2001) (73)
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. (2001) (73)
Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. (1995) (72)
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. (2000) (71)
Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPARγ Activation (2012) (71)
Prevention of stroke in patients with hypertension. (2007) (70)
Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy (2004) (69)
Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor &bgr;1 in the Rat Heart (2014) (67)
Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy (2013) (66)
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). (2005) (66)
Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study (2006) (65)
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk (2007) (65)
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). (2009) (65)
Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment: The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) (2009) (63)
In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study (2007) (63)
Regression of left ventricular hypertrophy--a meta-analysis. (1992) (63)
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study (2010) (62)
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study (2011) (61)
Effect of Lower On-Treatment Systolic Blood Pressure on the Risk of Atrial Fibrillation in Hypertensive Patients (2015) (61)
Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: The LIFE Study (2001) (61)
Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (2004) (61)
The cost‐effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension) (1993) (60)
A 5‐year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people (1994) (60)
Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential (2010) (59)
Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study (2012) (59)
Rationale, Design, and Methods (1997) (58)
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. (2004) (58)
Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well‐being (1997) (57)
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. (2001) (56)
Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP‐Hypertension‐2 (2004) (56)
Racial Differences in Incident Heart Failure During Antihypertensive Therapy (2011) (55)
Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide (1992) (55)
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. (1992) (54)
Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study (2008) (54)
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study (2004) (53)
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. (2009) (52)
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study (2008) (52)
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study (2007) (51)
Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). (2001) (50)
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy (2015) (50)
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). (2010) (49)
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. (2000) (49)
Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. (1993) (48)
Impact of lower achieved blood pressure on outcomes in hypertensive patients (2012) (46)
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. (2014) (46)
Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461-2469, doi: 10.1093/eurheartj/ehp363]. (2013) (45)
Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. (2011) (45)
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study (2010) (44)
Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure Control (2011) (44)
The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide (1993) (43)
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study (2010) (43)
The effect of baseline physical activity on cardiovascular outcomes and new‐onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study (2007) (41)
Echocardiographic Wall Motion Abnormalities in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study (2003) (40)
Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice (2016) (39)
STOP-hypertension: Swedish trial in old patients with hypertension. (1986) (39)
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. (2003) (39)
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy (2006) (39)
Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy: The LIFE (Losartan Intervention For Endpoint reduction in hypertension) Study (2005) (38)
Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice. (2015) (38)
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). (2005) (38)
Lisinopril and nifedipine in essential hypertension: a Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. (1991) (38)
Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy (2008) (38)
Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy (2005) (36)
Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study (2002) (36)
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol (2001) (35)
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. (2010) (35)
Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy (2007) (35)
Metabolic Syndrome, New Onset Diabetes, and New End points in Cardiovascular Trials (2006) (35)
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study (2009) (34)
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial−Blood Pressure Lowering Arm (ASCOT-BPLA) (2011) (34)
Single‐Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study (2012) (34)
Patients' and Physicians' Assessment of Risks Associated with Hypertension and Benefits from Treatment (1998) (33)
The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. (1996) (33)
A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study (2002) (32)
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. (2013) (32)
The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status. (1997) (31)
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). (2004) (30)
The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. (1993) (30)
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. (2005) (29)
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. (2009) (29)
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study (2004) (29)
Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy (2005) (29)
Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture (2015) (29)
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. (2012) (28)
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. (2005) (28)
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (2007) (27)
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study (2009) (27)
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study (2008) (27)
Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study (2003) (27)
The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure--insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). (1992) (27)
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study (2007) (26)
Effect of changing heart rate during treatment of hypertension on incidence of heart failure. (2012) (26)
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. (2012) (26)
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. (2004) (26)
Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist. (2009) (26)
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study) (2014) (26)
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study (2004) (26)
Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. (2012) (26)
Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade. (1983) (26)
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation (2010) (25)
Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA) (2005) (25)
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. (2013) (25)
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. (2004) (25)
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (2011) (24)
Serial assessment of the electrocardiographic strain pattern for prediction of new‐onset heart failure during antihypertensive treatment: the LIFE study (2011) (24)
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. (2009) (24)
Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study (2013) (24)
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study) (2004) (24)
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study (2009) (24)
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
Regression of left ventricular hypertrophy--are there differences between antihypertensive agents? (1992) (24)
Antihypertensive Effect of Felodipine or Hydralazine When Added to β‐Blocker Therapy (1988) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial (2004) (23)
Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT‐BPLA: comparison of their relative predictability using a novel approach (2011) (22)
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study (2006) (22)
Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone. (1993) (22)
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy (2007) (22)
Antihypertensive Efficacy and Tolerability of a Fixed Combination of Metoprolol and Felodipine in Comparison with the Individual Substances in Monotherapy (1990) (22)
The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone (2012) (22)
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen (2007) (21)
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study (2009) (21)
Calcium antagonists combined with beta-blockers or ACE inhibitors in the treatment of hypertension. (1988) (21)
Losartan benefits over atenolol in non‐smoking hypertensive patients with left ventricular hypertrophy: The LIFE study (2004) (20)
Relationship between salt and blood pressure in hypertensive patients on chronic ACE-inhibition. (1998) (20)
Left Ventricular Wall Stress–Mass–Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study (2015) (20)
Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy? (1999) (20)
Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. (2005) (20)
Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. (2001) (20)
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. (2008) (20)
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). (2009) (19)
Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study (2005) (19)
Additive effect of isradipine in combination with captopril in hypertensive patients. (1989) (19)
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension (2011) (19)
Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy. (1992) (19)
STOP-Hypertension--preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension. (1987) (19)
Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (2009) (18)
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. (2002) (18)
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study (2008) (17)
Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study (2004) (17)
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study (2017) (17)
Management of cardiovascular risk with RAS inhibitor/CCB combination therapy (2009) (17)
Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: The LIFE study (2011) (17)
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). (2011) (17)
ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data (2013) (16)
Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients. (1984) (16)
Losartan in essential hypertension: Effects on blood pressure and left ventricular maass (1995) (16)
Role of Blood Pressure and Other Variables in the Differential Cardiovascular Event Rates Noted in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA) (2005) (16)
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). (2002) (15)
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. (2009) (15)
Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study (2004) (15)
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). (2007) (15)
Regression of cardiovascular structural changes--a preventive strategy. (1990) (15)
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: The LIFE Study (2012) (15)
Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension — a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months — rationale and study design (2003) (14)
Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment (2014) (14)
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation (2015) (14)
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. (2010) (14)
In‐treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: The LIFE Study (2013) (14)
In-treatment stroke volume predicts cardiovascular risk in hypertension (2011) (14)
Association of Hemoglobin Delivery With Left Ventricular Structure and Function in Hypertensive Patients: Losartan Intervention For End Point Reduction in Hypertension Study (2006) (13)
The economic consequences of non‐adherence to lipid‐lowering therapy: results from the Anglo‐Scandinavian‐Cardiac Outcomes Trial (2010) (13)
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. (2012) (13)
Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study (2003) (13)
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study (2012) (12)
Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals (2013) (12)
Left ventricular wall stresses and wall stress–mass–heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study (2000) (12)
Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension. (1989) (12)
Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients. (1988) (12)
Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients (2011) (12)
Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study (2002) (11)
Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. (2003) (11)
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study) (2009) (11)
Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy (2013) (11)
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. (1994) (11)
Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design (2002) (11)
JIKEI HEART Study—A Morbi-Mortality and Remodeling Study with Valsartan in Japanese Patients with Hypertension and Cardiovascular Disease (2004) (11)
Long-term experience with the combination of pindolol and isradipine in essential hypertension (1988) (10)
REGRESSION OF LEFT VENTRICULAR HYPERTROPHY (1992) (10)
SINGLE-PILL COMBINATION OF TELMISARTAN 80 MG/AMLODIPINE 10 MG PROVIDES SUPERIOR BLOOD PRESSURE REDUCTIONS IN PATIENTS WITH SEVERE HYPERTENSION: TEAMSTA SEVERE HTN STUDY: HT.1.04 (2010) (10)
Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure (2007) (10)
Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group. (1993) (10)
Calcium antagonists in the treatment of hypertension: state of the art. (1990) (10)
Cost analysis of different pharmacological treatment strategies in elderly hypertensives (2005) (10)
Managing hypertension in the elderly (1992) (10)
Atenolol as a comparator in outcome trials in hypertension: A correct choice in the past, but not for the future? (2007) (10)
Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (2005) (9)
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. (2008) (9)
Prospects for the prevention of stroke (2006) (9)
882-1 Anglo-scandinavian cardiac outcomes trial — lipid-lowering arm (ASCOT-LLA): Results in the subgroup of patients with diabetes (2004) (9)
Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. (2003) (9)
Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). (2005) (9)
Clinical impact of ‘in-treatment’ wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study (2008) (9)
The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb (ASCOT-BPLA): effects in patients with type 2 diabetes (2006) (8)
Diuretics in the LIFE study (2004) (8)
Swedish Isradipine Study in Hypertension: Evaluation of Quality of Life, Safety, and Efficacy (1991) (8)
[Physical activity has a key role in hypertension therapy]. (2005) (8)
Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide. (1985) (8)
Prognostic significance of left ventricular hypertrophy during treatment of hypertension: The LIFE study (2003) (8)
Prevention of stroke: new evidence (2009) (8)
P-376: Left ventricular mass change during treatment and outcome in hypertensive patients with left ventricular hypertrophy: the LIFE trial (2002) (7)
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. (2014) (7)
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium (2012) (7)
758 THE RELATIONSHIP BETWEEN STATIN THERAPY AND PROGRESSION OF RENAL DAMAGE AMONG 10305 HYPERTENSIVE PATIENTS RANDOMISED IN THE ASCOT-LIPID-LOWERING ARM (LLA) (2011) (7)
Effects of Atenolol or Losartan on Fibrinolysis and von Willebrand Factor in Hypertensive Patients With Left Ventricular Hypertrophy (2010) (6)
Simplified echocardiography: an accurate and inexpensive method for the assessment of left ventricular hypertrophy. (1999) (6)
Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients (2009) (6)
The role of antihypertensive pharmacologic treatment in countering adverse pathophysiological profiles: influence on small arteries. (1987) (6)
Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. (2007) (6)
THE P.I.C.χE.L. STUDY: BENEFITS OF PRETERAX ON LVH REDUCTION (2004) (6)
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients (2018) (6)
Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study. (2010) (6)
Preventing stroke in hypertensive patients at risk. (2008) (5)
Association of left bundle branch block with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: the life study (2004) (5)
One year of antihypertensive treatment in patients with LVH: the life study. (1999) (5)
Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (2013) (5)
Was the LIFE trial independent? Author's reply (2002) (5)
Novel Therapeutics in Renal Diseases Prevention of diabetic nephropathy by compound 21 , selective agonist of angiotensin type 2 receptors , in Zucker diabetic fatty rats (2014) (5)
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study (2010) (5)
Drug treatment of hypertension. (1993) (5)
Improved blood pressure control with isradipine in hypertensive patients treated with pindolol. (1989) (5)
The long-term effect of isradipine in pindolol-treated patients. (1987) (4)
Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial (2015) (4)
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension. (1987) (4)
OR-27: The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) substudy (2003) (4)
OR-33: Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial (2002) (4)
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. (2003) (4)
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study (2012) (4)
A felodipine-metoprolol extended-release tablet: its properties and clinical development. (1995) (4)
812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study (2004) (4)
Left ventricular geometry and function in hypartensive patients with ECG left ventricular hypertrophy: the LIFE trial (1998) (4)
End-organ damage: does it really matter how we prevent it? (2003) (4)
Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance? (2000) (4)
Abstract 5533: Gender Differences in Outcome During Antihypertensive Therapy in Relation to Regression of Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study (2009) (4)
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy (2011) (4)
Pafenolol in Hypertension: A Double-Blind Randomized Trial of a New β1-Selective Adrenoceptor Blocker (1986) (4)
Comparison of the SCOPE and LIFE results. (2003) (3)
Further evidence for low-dose combinations in patients with left ventricular hypertrophy (2005) (3)
CARDIOVASCULAR COMPLICATIONS IN RELATION TO THE FRAMINGHAM RISK SCORE AND AGE IN HYPERTENSIVE PATIENTS WITH LVH: THE LIFE STUDY (2000) (3)
888-3 Racial differences in the prognostic value of the electrocardiographic strain pattern in hypertensive patients: The LIFE study (2004) (3)
The long-term antihypertensive efficacy and safety of a new felodipine-metoprolol combination tablet. The Swedish/UK and German Study Groups. (1993) (3)
The Effects of Telmisartan and Amlodipine in Treatment-Naïve and Previously Treated Hypertensive Patients: A Subanalysis from a 4 × 4 Factorial Design Study (2013) (3)
OMAPATRILAT IN PERSONS WITH ENHANCED RISK OF ATHEROSCLEROTIC EVENTS: THE OPERA TRIAL (2000) (3)
Renal outcomes with diff erent fi xed-dose combination therapies in patients with hypertension at high risk for cardiovascular events ( ACCOMPLISH ) : a prespecifi ed secondary analysis of a randomised controlled trial (2010) (3)
Regression of echocardiographic left ventricular hypertrophy in relation to resolution versus persistence of electrocardiographic strain after one year of antihypertensive therapy The LIFE study (2002) (3)
The Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA) New Insights into the Prevention of Cardiovascular Events with the Newer versus the Older Antihypertensive Regimen (2005) (3)
Effect and tolerability of combining lovastatin with nifedipine or lisinopril. (1993) (3)
Gender differences in regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study (2003) (3)
Does aortic valve sclerosis predict cardiovascular events independently of albuminuria in hypertension? A LIFE study (2003) (3)
DIRECT ANGIOTENSIN AT2-RECEPTOR STIMULATION IMPROVES SURVIVAL AND NEUROLOGICAL OUTCOME IN EXPERIMENTAL STROKE (MCAO) IN MICE: 4A.07 (2011) (3)
Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension. (2020) (2)
Key learnings from the STOP-Hypertension study: An update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly (2004) (2)
Abstract 4421: Concomitant Hydrochlorothiazide Therapy in Hypertensive Patients is Associated with Reduced Cardiovascular Morbidity and Mortality Independent of Blood Pressure and Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study (2008) (2)
The effect of losartan versus atenolol on aortic valve sclerosis: A LIFE study (2003) (2)
Abstract 2995: Impact of Atenolol versus Losartan-Based Treatment on Aortic Root Dilatation in Hypertension: The LIFE Study (2006) (2)
Factors Involved in the Pathogenesis of Hypertensive Cardiovascular Hypertrophy (2012) (2)
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]. (2003) (2)
PERSISTENCE OF LEFT VENTRICULAR HYPERTROPHY IS ASSOCIATED WITH MARKEDLY WORSE OUTCOMES IN PATIENTS WITH LOWER ACHIEVED SYSTOLIC PRESSURE (?130 MM HG) DURING ANTIHYPERTENSIVE TREATMENT: THE LIFE STUDY (2011) (2)
Definition of high blood pressure, epidemiology and goals of hypertension treatment. (1998) (2)
Diuretics in the LIFE study - Reply (2004) (2)
B018: Age-dependent event rate and reduction of coronary risk in hypertensive patients with LVH: The life study (2000) (2)
Swedish trial in old patients with hypertension. A prospective multicentre study in Swedish primary health care. (1986) (2)
Relationship between change in erythrocyte sodium and antihypertensive response to enalapril. (1994) (2)
DIFFERENT EFFECTS OF ANTIHYPERTENSIVE THERAPIES BASED ON LOSARTAN OR ATENOLOL ON ULTRASOUND AND BIOCHEMICAL MARKERS OF MYOCARDIAL FIBROSIS: P2.70 (2004) (2)
Abstract 1881: Association of New-Onset Left Bundle Branch Block with Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE study (2006) (2)
Cardiovascular Risk Reduction in Hypertensive Black Patients With Left Ventricular Hypertrophy The (2016) (2)
Abstract 1349: The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) (2009) (2)
Valsartan and the renin-angiotensin-aldosterone system: Blood pressure control and beyond (2000) (2)
P-398: Systolic left ventricular function improves more by beta-blokade than losartan: the life study (2003) (1)
[ACE inhibitors in pregnancy can be harmful to the fetus]. (1986) (1)
Abstract 3701: Better Preservation of Left Atrial Systolic Force By Losartan may Contribute to Lower Incidence of New-onset Atrial Fibrillation: The LIFE study (2006) (1)
1009-166 Pulse pressure as cardiovascular risk marker during losartan or atenolol based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial) (2004) (1)
RACIAL DIFFERENCES IN SUDDEN CARDIAC DEATH AMONG HYPERTENSIVE PATIENTS DURING ANTIHYPERTENSIVE THERAPY: THE LIFE STUDY (2011) (1)
ACE inhibitors: the evidence in hypertension. (1999) (1)
Abstract 1449: Racial Differences in Incident Heart Failure Among Hypertensive Patients During Antihypertensive Therapy: The LIFE Study (2009) (1)
Arterial stiffness and left ventricular geometry and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study (2002) (1)
Treatment of Hypertension with Calcium Antagonists (1989) (1)
OR-21: Relation of serum uric acid to cardiovascular endpoints in hypertension: the life study (2003) (1)
Association of Left Ventricular Hypertrophy Regression and Heart Rate Reduction With Determinants of Myocardial Oxygen Consumption and Cardiovascular Events: The LIFE Study (2003) (1)
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially in elderly patients with hypertension and left ventricular hypertrophy on ECG. : The LIFE study (2006) (1)
THE IMPORTANCE OF BLOOD PRESSURE VARIABILITY FOR SUBCLINICAL ORGAN DAMAGE AND CARDIOVASCULAR EVENTS. A LIFE SUBSTUDY: 8C.07 (2010) (1)
Abstract 9371: Low In-Treatment HDL Cholesterol Strongly Predicts Incident Atrial Fibrillation: The LIFE Study (2012) (1)
[Lisinopril and nifedipine have neutral effects on lipids]. (1994) (1)
888-2 Does left ventricular hypertrophy predict sudden cardiac death independent of ischemia? The LIFE study (2004) (1)
P-246: Left ventricular mass changes in patients with isolated systolic or combined hypertension and echocardiographic left ventricular hypertrophy: the life study (2003) (1)
Is urinary albumin excretion an independent predictor of cardiovascular mortality in patients with electrocardiographic left ventricular hypertrophy? The LIFE study (2002) (1)
P-374: Differences in heart rate variabilty in African-American vs Caucasian hypertensives with left ventricualr hypertrophy: the LIFE study (2002) (1)
[Treatment with lisinopril or nifedipine in essential hypertension. A Norwegian multicenter study of the effect, tolerance and quality of life of 828 patients]. (1992) (1)
[Cough during treatment with angiotensin-converting enzyme inhibitors is gender related]. (1992) (1)
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study (2010) (1)
Angiotensin AT2R stimulation improves glucose tolerance and insulin sensitivity in obese mice (2011) (1)
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study (2006) (1)
ALBUMINURIA PREDICTS CARDIOVASCULAR OUTCOME ON TREATMENT WITH LOSARTAN VERSUS ATENOLOL IN PATIENTS WITH DIABETES, HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY? A LIFE DIABETES SUBSTUDY: OP 085 (2004) (1)
Primary Prevention of Atrial Fibrillation in Hypertensive Patients: What Is New from the LIFE Trial? (2006) (1)
Extending the benefits of combination antihypertensive therapy to morbidity and mortality reduction (2004) (1)
Response from Merck (2003) (1)
Abstract 8654: Low In-Treatment HDL Cholesterol Levels Strongly Predict New Heart Failure in Hypertensive Patients: The LIFE Study (2011) (1)
Diuretics in the LIFE study. Authors' reply (2004) (1)
152 Additive effect of isradipine in combination with captopril in hypertensive patients (1988) (1)
1163-111 Myocardial performance index independently predicts cardiovascular morbidity and mortality in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study (2004) (1)
Abstract 9245: Incident Atrial Fibrillation is Associated with an Increased Risk of Sudden Cardiac Death in Hypertensive Patients During Antihypertensive Therapy: The LIFE Study (2011) (0)
7.2 Mitral E Wave Deceleration Time to Peak E Velocity Ratio and Cardiovascular Outcome in Hypertensive Patients during Anti-Hypertensive Treatment: the Life Study (2008) (0)
ACCOMPLISH trial Design and rationale (2003) (0)
P-416: Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy: the life study (2003) (0)
[PP.21.10] PATIENTS BETTER THAN PHYSICIANS IN ESTIMATING 10-YEAR RISK OF HYPERTENSION-RELATED CARDIOVASCULAR MORBIDITY – COHORT STUDY (2017) (0)
1085-166 Does hormone replacement therapy in women influence their benefit of losartan-treatment in the LIFE study? (2004) (0)
Abstract 3267: Gender Difference in the Association of Aortic Valve Sclerosis and Cardiovascular Events in Hypertensive Adults with Left Ventricular Hypertrophy: The LIFE Study (2007) (0)
Abstract 3001: Regression of the Electrocardiographic Strain Pattern Between Baseline and One Year of Antihypertensive Treatment is Strongly Associated With Regression of Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study (2006) (0)
[Aerobic physical activity lowers blood pressure in hypertension]. (2015) (0)
[Treatment of hypertension in Norway. Indications, therapeutic intensity and economic aspects]. (1992) (0)
Age-related changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The preserve study. (1999) (0)
[Review of new pharmacological treatment principles in hypertension]. (1983) (0)
RELATIONSHIPS BETWEEN SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HIGH RISK HYPERTENSION: AN ANALYSIS OF THE ACCOMPLISH TRIAL (2013) (0)
EVALUATION OF DRUG ADHERENCE AND HYPERTENSION CONTROL RATE IN THE ELDERLY (2011) (0)
2.19 Are Coronary Revascularisation and Myocardial Infarction a Logical Combined Endpoint in Hypertension Trials? The Life Study (2007) (0)
REDUCED ECG-LVH DURING ANTIHYPERTENSIVE THERAPY IS ASSOCIATED WITH LESS HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH ISOLATED SYSTOLIC HYPERTENSION. THE LIFE STUDY: 1A.01 (2010) (0)
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction. (2008) (0)
LOW IN-TREATMENT HDL CHOLESTEROL LEVELS STRONGLY PREDICT THE DEVELOPMENT OF NEW STROKE: THE LIFE STUDY (2013) (0)
[Hypertensive crises are rare conditions. Uncritical use of intravenous antihypertensive agents can be more harmful than useful]. (1986) (0)
Abstract 19085: Prevalence and Correlates of Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy (The LIFE Study) - Application of New Multivariate Predictive Models. (2010) (0)
Potential Clinical Application of Angiotensin 2 Receptor Agonists (2015) (0)
INFLUENCE OF DIABETES ON LEFT VENTRICULAR MASS REGRESSION WITH ALISKIREN, LOSARTAN OR BOTH (2011) (0)
Antihypertensive Therapy (1966) (0)
Abstract 3269: Association of Aortic Regurgitation with Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricle Hypertrophy: The LIFE study (2007) (0)
PROTECTIVE EFFECT OF VALSARTAN FOR STROKE IN JAPANESE SUBJECTS: AN ANALYSIS OF JIKEI HEART STUDY: PP.37.233 (2011) (0)
Competing effects of hypokalemia and hydrochlororothiazide treatment on regression of Cornell product left ventricular hypertrophy in hypertensive patients : implications for the development of potassium-sparing diuretics (2009) (0)
Abstract 3617: The Relation of New Atrial Fibrillation to Cardiovascular and All-Cause Mortality During Treatment of Hypertension: The LIFE Study (2007) (0)
The effect of baseline physical activity on cardiovascular outcomes in patients treated for hypertension with LVH. (2004) (0)
[Ambulatory blood pressure measurement--guidelines for registration and data processing]. (1991) (0)
Abstract 2757: Development of New Electrocardiographic Strain Pattern is Associated With an Increased Risk of Cardiovascular Morbidity and Mortality During Antihypertensive Treatment: The LIFE Study (2006) (0)
STATIN USE AND RISK OF NEW DIABETES MELLITUS IN HYPERTENSivE PATIENTS: THE LIFE STUDY (2013) (0)
Abstract 2281: Mitral E Wave Deceleration Time to Peak E Velocity Ratio And Cardiovascular Outcome in Hypertensive Patients During Anti-Hypertensive Treatment: the LIFE Echo-Substudy. (2007) (0)
Abstract 9732: Mitral Annular Calcification and Incident Embolic Stroke in Treated Hypertensive Patients: The LIFE Echo-Substudy (2011) (0)
Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Hypertension (2006) (0)
Association of hypokalemia with Cornell product left ventricular hypertrophy independant of treatment and blood pressure in hypertensive patients : implications for the development of new diurectic anthihypertensives (2009) (0)
ASCOT-BPLA - Authors' reply (2006) (0)
Abstract 4434: Association of Elevated Serum Glucose Levels with Hypokalemia Independent of Treatment in Hypertensive Patients: Implications for the Development of New Diabetes (2008) (0)
Effects of ACE inhibition on the hypertrophied heart‐implications for reversal and prognosis: An updated review (1995) (0)
Dr Lowe has received funding for investigator-initiated (2002) (0)
Losartan reduces hospitalization for heart failure in patients with diabetes and no prior history of heart failure (2003) (0)
P-529: Association between oxygen delivery and left ventricular mass diastolic dysfunction in hypertensives with electrocardiographic left ventricular hypertrophy: The life study (2001) (0)
1029 AT2 receptor stimulation and vascular remodeling in L-NAME-induced Hypertension (2012) (0)
Implications of recent end-point trials on future management of hypertension and dyslipidaemia (2004) (0)
Abstract 10213: Digoxin Use and Risk of Mortality in Hypertensive Patients With Atrial Fibrillation: The LIFE Study (2013) (0)
LACK OF REGRESSION OF LEFT VENTRICULAR HYPERTROPHY IS ASSOCIATED WITH CARDIOVASCULAR MORTALITY AFTER REVASCULARIZATION IN HYPERTENSIVES. THE LIFE STUDY: 7C.01 (2010) (0)
Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review. (1990) (0)
Abstract 1833: Relationship of Left Atrial Enlargement to Persistence or Development of Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients: Implications for the Development of New Atrial Fibrillation (2006) (0)
Abstract 16803: Gender Differences in the Impact of Arterial Stiffness on Outcome in Hypertensive Patient With Left Ventricular Hypertrophy (The Life Study) (2013) (0)
Abstract 20657: The Incidence and Risk of Hypokalemia in Patients With High Risk Hypertension: The ACCOMPLISH Study (2010) (0)
ANGIOTENSIN AT2R STIMULATION IMPROVES GLUCOSE TOLERANCE AND INSULIN SENSITIVITY IN OBESE MICE: 1D.05 (2011) (0)
P-242: Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): blood pressure changes at 2.5 years of follow-up (2002) (0)
Responses to: The codex of science: honesty, precision, and truth-and its violations. (2013) (0)
Lessons from STOP-Hypertension (1994) (0)
[BBB--a Swedish multicenter study. Can hypertension be better treated?]. (1988) (0)
[Protection from stroke, updates and perspectives]. (2004) (0)
[Antihypertensive treatment reduces the risk of stroke even in elderly hypertensive patients]. (1991) (0)
Introduction (2005) (0)
[Hypertension therapy with beta blocker plus diuretic. "We are at the point of leaving behind an era"]. (2005) (0)
Response to Spironolactone in Resistant Hypertension (2007) (0)
AN INNOVATIVE PHASE 2 CLINICAL TRIAL DESIGN FOR ASSESSMENT OF CS1: A NOVEL THERAPY IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (2022) (0)
Picxel: perindopril/indapamide has a greater benefit on left ventricular hypertrophy than enalapril (2004) (0)
Was the LIFE trial independent? (2002) (0)
ASCOT-LLA: questions about the benefits of atorvastatin (2003) (0)
OR-48: Does losartan treated patients with albuminuria have better cardiovascular outcome than those treated with atenolol? The LIFE study (2002) (0)
THE EFFECT OF BASELINE PHYSICAL ACTIVITY ON CARDIOVASCULAR OUTCOMES IN PATIENTS TREATED FOR HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: P3.323 (2004) (0)
Is albuminuria a cardiovascular risk factor independent of left ventricular hypertrophy in hypertension? A LIFE study (2003) (0)
Antihypertensive drugs and plasma lipids. (1992) (0)
Hypertensive patients with diabetes have less regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study (2003) (0)
Stroke outcomes in life (2003) (0)
Abstract 4152: Did Older or Younger Patients Benefit More from Amlodipine based vs Atenolol based Therapy in ASCOT-BPLA? (2006) (0)
More on the LIFE study. Author's reply (2003) (0)
Ethnicity, left ventricular hypertrophy regression and cardiovascular events in the life echocardiography substudy (2004) (0)
PCV29 COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS.TREATED FOR HYPERTENSION: THE ASCOT-LLA STUDY (2004) (0)
Is the severity of hypertension related to different cardiac features in patients with left ventricular hypertrophy? The preserve study. (1999) (0)
7. Relationship between HLA-antigens and hypertension in individuals with a positive family history of hypertension (1991) (0)
Pharmacological properties of beta-adrenoceptor blockers in relation to their antihypertensive effect. (2009) (0)
Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice (2016) (0)
Epidemiology and CKD - 1 (2009) (0)
[Mild hypertension--risks and therapeutic strategies]. (1984) (0)
COMBINED USE OF ELECTROCARDIOGRAM AND ECHOCARDIOGRAM TO BETTER IDENTIFY HYPERTENSIVE PATIENTS AT HIGH RISK FOR HEART FAILURE: 4C.06 (2010) (0)
A028: Regression of left ventricular hypertrophy does not improve ventricular arrhythmogenecity-six month results: A life sub-study (2000) (0)
Abstract 19856: No Impact of Weight Gain on Blood Pressure and Left Ventricular Mass Variation in Hypertensive Patients with Left Ventricular Hypertrophy: the LIFE Study. (2010) (0)
78. The SWISH study (Swedish Isradipine Study in Hypertension): evaluation of quality of life and efficacy in 587 patients (1991) (0)
The relationship of in-treatment serum glucose to all-cause mortality and cardiovascular morbidity and mortality in hypertensive patients without known diabetic during treatment : the LIFE study (2009) (0)
PCV55 COST-EFFECTIVENESS OF VALSARTAN IN JAPAN: RESULTS FROM THE JIKEI HEART STUDY (2009) (0)
Abstract 9424: Low In-Treatment HDL Cholesterol Levels Strongly Predict the Development of New Diabetes Mellitus: The LIFE Study (2010) (0)
4.20 Clinical Impact of Changes in Wall Motion Abnormalities in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study (2007) (0)
P-134: Older age does not attenuate hypertrophy regression during antihypertensive treatment in hypertensive patients with left ventricular hypertrophy (the life study) (2003) (0)
Abstract 5420: Suppression of Aldosterone Mediates Left Ventricular Hypertrophy Regression in Patients With Hypertension (2009) (0)
371 THE AT2 RECEPTOR AND VASCULAR REMODELING (2012) (0)
Chapter 31 – The LIFE Study (2005) (0)
B011: The Anglo-Scandinavian cardiac outcomes trial (ASCOT)—demography of first 15000 patients randomised (2000) (0)
Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study (2002) (0)
compared to an atenolol-based regimen amlodipine-based regimen is cost-effective Antihypertensive treatment with an Economic Evaluation of ASCOT-BPLA : (2007) (0)
Abstract 9199: Racial Differences in Incident Atrial Fibrillation Among Hypertensive Patients During Antihypertensive Therapy: The LIFE Study (2010) (0)
Abstract 20076: Effect of Combination Therapy with Benazepril/Amlodipine Compared with Benazepril/Hydrochlorothiazide in Patients with High-Risk, Stage 2 Hypertension with or Without Known Coronary Artery Disease (2010) (0)
Abstract 12734: A New 4-group Classification of Left Ventricular Hypertrophy Based on left Ventricular Geometry Located a New High-risk Group within Eccentric Hypertrophy in Hypertensive Patients - A LIFE Study (2012) (0)
Abstract 13771: Association of a Renin Genetic Polymorphism With Left Ventricular Mass Regression in Hypertensive Patients Treated With Aliskiren, Losartan, or Both (2011) (0)
Abstract 5862: Development of Systolic Dysfunction Not Related to Myocardial Infarction in Treated Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Echo Substudy (2009) (0)
Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment in patients with electrocardiographic left ventricular hypertrophy (LIFE) (2013) (0)
Oral Sessions (2014) (0)
Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: : A LIFE substudy (2004) (0)
The LIFE sudy (2005) (0)
[A review of recent pharmacological therapeutic principles in hypertension]. (1983) (0)
Abstract 5419: Hypokalemia Blunts Left Ventricular Mass Regression in Hypertensive Patients During Losartan- or Atenolol-Based Treatment: The LIFE Echo-substudy (2009) (0)
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension (2006) (0)
PRINCIPAL RESULTS OF THE NORDIL HYPERTENSION TRIAL – A COMPARISON BETWEEN DILTIAZEM AND DIURETIC/BETABLOCKER BASED TREATMENT: P2.46 (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Björn Dahlöf?

Björn Dahlöf is affiliated with the following schools: